Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: Labrador who wrote (5143)

3/11/2019 1:11:49 PM

From: richardred

Respond to of 7256

This massive acquisition most definitely caught my attention. Personally I have mixed feelings. IMO good for Celgene holders not so much for BMY holders near term. With thoughts of falling behind competitors in oncology. I feel BMY felt they had to make the big plunge acquisition because their was nothing available in oncology, in scale to be a leader. Celgene already built itself through big and small acquisitions. This took much off the market. It seems some of BMY holders are not happy about the deal. Of course, I could be wrong, but I think the deal gets approved. Celgene already has scale in the Cancer field with approved products and is very profitable with good cash flow. Good luck in your mission. Current 17%-18% gain on a 50 BMY price & 50 in cash.

From: richardred 1/3/2019 9:53:02 AM

Read Replies (1) of 5143

Major Acquisition to start the new year. The same way last year started.

Bristol-Myers to buy Celgene in $74B deal

cnbc.com

From: richardred 1/22/2018 11:16:51 AM

Read Replies (1) of 5112

A Merger Monday. Mainly in the Bio-Pharma space.

Juno Therapeutics acquired by Celgene for $9B in dramatic deal for rising biotech star.
geekwire.com

Sanofi digs deep to buy U.S. hemophilia group Bioverativ for $11.6 billion
reuters.com

AIG to Acquire Validus for $5.56 Billion in Cash

businesswire.com

To: Labrador who wrote (5143)	3/26/2019 12:37:43 PM
From: richardred	Read Replies (1) \| Respond to of 7256

IMO most definitely a tough ARB play. Possible delay? Plus positive news for Celgene -Celgene (CELG) Submits Application to FDA for Ozanimod for Treatment of Relapsing Forms of MS. streetinsider.com Would BMS-Celgene control too much of the psoriasis business? FTC wants to find out by Carly Helfand \| Mar 26, 2019 12:00pm The FTC has asked for more info on BMS and Celgene's psoriasis products. (Wikimedia Commons) ShareFacebook Twitter LinkedIn Email Print Turns out shareholders aren’t the only ones who have some issues with Bristol-Myers Squibb’s proposed $74 billion Celgene merger. The Federal Trade Commission (FTC) is taking a closer look at the companies’ psoriasis drugs, both those on the market and those making their way through the clinic, Celgene said in a regulatory filing (PDF). The agency asked Bristol-Myers and Celgene Monday to hand over additional info and documents about their respective drugs. Celgene said the companies “will continue to cooperate with the FTC staff in its review of the transactions contemplated by the Merger Agreement.” Right now, Bristol and Celgene don’t think the review will throw off their deal timeline; they still expect the transaction to wrap in this year’s third quarter. But a potential overlap in psoriasis offerings, as determined by the FTC, could result in castoffs of marketed or pipeline products—a scenario that could hurt the combined company's prospects as it aims to become a top immunology player. RELATED: Celgene notches positive Otezla data in scalp psoriasis as it guns for market expansion Celgene sells Otezla, a next-generation pill that treats the skin disease. Sales have ramped up lately, with the therapy churning out $448 million in the fourth quarter to surpass last year’s haul in the same period by more than 20%. And the New Jersey drugmaker is still looking to widen Otezla’s reach: In October, it posted positive phase 3 study results in scalp psoriasis. Bristol-Myers, meanwhile, wants to upend the market with its own psoriasis newcomer, a fellow oral option currently in phase 3. Last September, the candidate put up stellar phase 2 results, showing it could dramatically reduce symptoms in 12 weeks of treatment. RELATED: Can BMS rebels scuttle its Celgene buy? Analysts do the math—and so far, the votes don't add up But the FTC isn’t the only force that could potentially stop the two drugmakers from joining forces. Activist investor Starboard Value has been trying to thwart the mammoth merger by rallying “no” votes from fellow shareholders—such as top stakeholder Wellington Management, which has already come out against the deal. Analysts, though, say for the time being that they still foresee the transaction going through. fiercepharma.com